| 1.83 -0.06 (-3.17%) | 06-17 10:35 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.23 |
1-year : | 2.42 |
| Resists | First : | 1.91 |
Second : | 2.07 |
| Pivot price | 1.85  |
|||
| Supports | First : | 1.65 |
Second : | 1.38 |
| MAs | MA(5) : | 1.89 |
MA(20) : | 1.82 |
| MA(100) : | 1.88 |
MA(250) : | 3.3 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 42.6 |
D(3) : | 51.8 |
| RSI | RSI(14): 48.3 |
|||
| 52-week | High : | 8.22 | Low : | 1.3 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ NKTX ] has closed above bottom band by 43.1%. Bollinger Bands are 43.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.89 - 1.9 | 1.9 - 1.91 |
| Low: | 1.8 - 1.81 | 1.81 - 1.82 |
| Close: | 1.87 - 1.89 | 1.89 - 1.91 |
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Tue, 10 Jun 2025
Nkarta (NKTX) Maintains Outperform Rating as Mizuho Lowers Price Target | NKTX Stock News - GuruFocus
Tue, 10 Jun 2025
Nkarta (NKTX) Price Target Reduced by Mizuho | NKTX Stock News - GuruFocus
Fri, 06 Jun 2025
Nkarta Taps Sotyktu, Stelara Developer as New CMO to Lead Autoimmune Disease Push - Stock Titan
Mon, 19 May 2025
Nkarta (NKTX) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance
Thu, 15 May 2025
Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune Space - Nkarta (NASDAQ:NKTX) - Benzinga
Wed, 14 May 2025
Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 71 (M) |
| Shares Float | 52 (M) |
| Held by Insiders | 5 (%) |
| Held by Institutions | 91.7 (%) |
| Shares Short | 7,570 (K) |
| Shares Short P.Month | 7,200 (K) |
| EPS | -1.46 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.34 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -15.2 % |
| Return on Equity (ttm) | -26.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.66 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -101 (M) |
| Levered Free Cash Flow | -64 (M) |
| PE Ratio | -1.27 |
| PEG Ratio | 0 |
| Price to Book value | 0.34 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.29 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|